AMOYTOP released its performance for the first half of the year, with a net profit attributable to the parent company of 428 million yuan, an increase of 40.60%
I'm LongbridgeAI, I can summarize articles.AMOYTOP released its semi-annual report for 2025, with operating revenue of 1.511 billion yuan, a year-on-year increase of 26.96%; net profit attributable to the parent company was 428 million yuan, a year-on-year increase of 40.60%. The net profit after deducting non-recurring gains and losses was 431 million yuan, a year-on-year increase of 30.68%. The basic earnings per share were 1.05 yuan. The growth in performance was mainly attributed to the popularization of the clinical cure concept for hepatitis B and the increase in patients treated with the core product, Peginterferon
According to the Zhitong Finance APP, AMOYTOP (688278.SH) released its semi-annual report for 2025, showing an operating income of 1.511 billion yuan, a year-on-year increase of 26.96%. The net profit attributable to shareholders of the listed company was 428 million yuan, a year-on-year increase of 40.60%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 431 million yuan, a year-on-year increase of 30.68%. The basic earnings per share were 1.05 yuan.
During the reporting period, the company's operating income increased by 26.96% year-on-year, mainly due to the continuous popularization of the concept of clinical cure for hepatitis B and the accumulation of scientific evidence, leading to a steady increase in the number of patients receiving treatment with the company's core product, Peginterferon